Gray market peptides column cites ER survey it does not name
A nurse practitioner's MassLive column says 3 in 10 of 1,000 peptide users went to an emergency room but names no survey. Its other warnings match what regulators have found.
WESTFIELD, MASS.
3 in 10Peptide users who visited an ER in a 1,000 person survey the column cites but does not name
- What's newA MassLive health column by a Westfield nurse practitioner warns that gray market peptides cause harm, citing a survey in which 3 in 10 of 1,000 users visited an emergency room. The column does not name the survey.
- Why it mattersThe column adds a clinician's voice against unapproved peptides as a federal policy opens pharmacy compounding to six of them, but its headline figure cannot be checked without a named source.
- What's nextPublic comments on the interim HHS compounding policy close November 13, and a final rule is still pending. A Johns Hopkins physician scientist quoted in the column is seeking federal funding to study peptides.
